Monthly Archives: July 2018

Global Diabetes Drug Market Size 2018, Share, Trends | Forecast 2025 by Global QYResearch

The research report titled Global Diabetes Drug Market Professional Survey Report 2018 market size and forecast and overview on current market trends

London, United Kingdom – July 30, 2018 /MarketersMedia/

The “Global Diabetes Drug Market Professional Survey Report 2018” is an in depth study analyzing the current state of the Global Diabetes Drug Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Global Diabetes Drug Market provides analysis of China market covering the industry trends, recent developments in the market and competitive landscape. Competitive analysis includes competitive information of leading players in China market, their company profiles, product portfolio, capacity, production, and company financials. In addition, report also provides upstream raw material analysis and downstream demand analysis along with the key development trends and sales channel analysis. Research study on Global Diabetes Drug Market discusses the opportunity areas for investors.

The report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Download Sample Copy Of This Report: http://globalqyresearch.com/download-sample/509200

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
North America
Europe
China
Japan
India
Southeast Asia
Other regions (Central & South America, Middle East & Africa)

We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Saudi Arabia
Turkey
Rest of Middle East & Africa

Ask Query Here: edwin@globalqyresearch.com or Sales@globalqyresearch.com

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Insulin
Sensitizers
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Secretagogues
Peptide Analogs
Others

By Application, the market can be split into
Hospital
Clinic
Others

The study objectives of this report are:
To analyze and study the global Diabetes Drug capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
Focuses on the key Diabetes Drug manufacturers, to study the capacity, production, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Diabetes Drug are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders
Diabetes Drug Manufacturers
Diabetes Drug Distributors/Traders/Wholesalers
Diabetes Drug Subcomponent Manufacturers
Industry Association
Downstream Vendors

Available Customizations
With the given market data, Global QYResearch offers customizations according to the company’s specific needs. The following customization options are available for the report:
Regional and country-level analysis of the Diabetes Drug market, by end-use.
Detailed analysis and profiles of additional market players.

View Detail Report With Complete Table of Content, List of Table and Figure@ http://globalqyresearch.com/global-diabetes-drug-market-professional-survey-report-2018

Table of Contents :

1 Industry Overview of Diabetes Drug

2 Manufacturing Cost Structure Analysis of Diabetes Drug

3 Technical Data and Manufacturing Plants Analysis of Diabetes Drug

4 Global Diabetes Drug Overall Market Overview

5 Diabetes Drug Regional Market Analysis

6 Global 2013-2018E Diabetes Drug Segment Market Analysis (by Type)

7 Global 2013-2018E Diabetes Drug Segment Market Analysis (by Application)

8 Major Manufacturers Analysis of Diabetes Drug

9 Development Trend of Analysis of Diabetes Drug Market

10 Diabetes Drug Marketing Type Analysis

11 Consumers Analysis of Diabetes Drug

12 Conclusion of the Global Diabetes Drug Market Professional Survey Report 2017

The report is readily available and can be dispatched within 4hr after payment confirmation.

Buy This Premium Report:

For Single User License@ http://globalqyresearch.com/checkout-form/0/509200

For Corporate (Multi) User License@ http://globalqyresearch.com/checkout-form/1/509200

Contact Info:
Name: Edwin Fernandez
Email: edwin@globalqyresearch.com
Organization: Global QYResearch
Address: Unit1, 26 Cleveland Road, South Woodford, London, E182AN, United Kingdom
Phone: +44 20 3286 1546

Source URL: https://marketersmedia.com/global-diabetes-drug-market-size-2018-share-trends-forecast-2025-by-global-qyresearch/386135

For more information, please visit http://globalqyresearch.com

Source: MarketersMedia

Release ID: 386135

AKER NOTICE: Pawar Law Reminds of Important August 13, 2018 Lead Plaintiff Deadline in Class Action – AKER

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Pawar Law Group reminds shareholders who purchased shares of Akers Biosciences, Inc. (NASDAQ: AKER) from May 15, 2017 through June 5, 2018 (the “Class Period”) of the important August 13, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Akers Biosciences investors under the federal securities laws. To join the Akers Biosciences class action, go to http://pawarlawgroup.com/cases/akers-biosciences-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) as a result, defendants’ statements about Akers’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 13, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/akers-biosciences-inc/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll-Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 507416

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Rockwell Medical, Inc. – RMTI

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Rockwell Medical, Inc. (NASDAQ: RMTI) between March 16, 2018 and June 26, 2018, inclusive (the ”Class Period”). The lawsuit seeks to recover damages for Rockwell investors under the federal securities laws.

To join the Rockwell class action, go to http://pawarlawgroup.com/cases/rockwell-medical-inc/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that the Centers for Medicare and Medicaid Services would not pursue Rockwell’s proposal for separate reimbursement for Triferic; (2) the estimated reserves in Rockwell’s Form 10-Q for the quarter ended March 31, 2018 were misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) defendant Robert L. Chioini, Rockwell’s former Chief Executive Officer, withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of Rockwell’s Board; and (6) as a result, defendants’ statements about Rockwell’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 25, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/rockwell-medical-inc/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 507413

Alexa Rostovksy Joins Talk Project, a Summer 2018 Peer-to-Peer Sexual Violence Prevention Program for Los Angeles High School Students

BEVERLY HILLS, CA / ACCESSWIRE / July 30, 2018 / While many high school students are working summer jobs or taking a break from curricular studies, Alexa Rostovsky, soon-to-be junior at Los Angeles’ Harvard Westlake School, will be training to become a youth leader with the Talk Project– ‘a cultural movement and effective educational workshop designed by students for students to combat sexual violence’. This unique peer-to-peer model is an initiative of the National Council of Jewish Women with proven results, offering program participants a holistic, interactive learning approach framed by inclusivity. In her role as an educator, Ms. Rostovsky intends to tackle the prevalent and persistent issue of sexual violence which Forbes describes as ‘an epidemic’ with 1 in 3 women and 1 in 6 men in the United States experiencing some form of abuse over the course of their lives, according to data compiled by the NSVRC.

Reflecting on her motivation to join the project, Alexa Rostovsky recalls being inspired by a presentation delivered by like-minded student educators to her sophomore year ‘Choices and Challenges’ class. She describes her excitement to participate in the program and to educate others as an opportunity towards ‘creating a cultural shift and something I can personally do to help put an end to this rape violence that has become detrimental to our society’. Building on the momentum of movements such as #MeToo and the Women’s March on Washington (the most attended protest in the United States since the 1960s-70s as reported by the Washington Post), Rostovsky looks forward to increasing awareness and inspiring change amongst her peers.

An astounding research report published by the National Institute for Justice which examines the economic ramifications of crime reveals that annual costs related to rape (USD $127 billion) exceed all other crimes (eg. assault [$93 billion], murder [$71 billion]) by a significant margin. Faced with hard truths such as these, Alexa Rostovsky explains she is driven to contribute towards positive change in society and a safer, more informed culture-aims which Talk Project seeks to facilitate through youth empowerment. Created and presented by students for students, the Talk Project offers participants an opportunity to strengthen their own skills in advocacy, teamwork, communications, and public speaking. Studies have found that program participants are significantly less likely to believe in rape
myths, and more likely to engage in protective behaviors and intervene if confronted with situations linked to sexual violence. An important component of the initiative
are paired screenings of the award-winning documentary The Hunting Ground, a film that examines the sexual violence epidemic facing American colleges. The Talk Project workshop is free and offered to Los Angeles area high school students. Visit ChangeTheTalk.org for more information.

Alexa Rostovsky dedicates much of her time to worthy endeavors in support of her community, having previously been bestowed by her school with the Humanitas Award in recognition of her volunteer work for numerous causes, including the Grossman Burn Foundation and a remote reading program benefiting children with learning disabilities. In her spare time, Alexa nurtures a passion for the culinary arts, horseback riding, dance and is a talented flautist.

Contact Information:

StevenRostovskyNews.com
contact@stevenrostovskynews.com
http://stevenrostovskynews.com

SOURCE: Alexa Rostovksy

ReleaseID: 507421

Unum Group NOTICE: Pawar Reminds of Important August 13, 2018 Lead Plaintiff Deadline in Class Action – UNM

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Pawar Law Group reminds shareholders who purchased shares of Unum Group (NYSE: UNM) between January 31, 2018 and May 2, 2018, both dates inclusive (the “Class Period”) of the important August 13, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Unum investors under the federal securities laws.

To join the Unum class action, go to http://pawarlawgroup.com/cases/unum-group/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. You may also remain an absent class member and do nothing at this point. You may retain counsel of your choice.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Unum was experiencing a higher claims incidence for its long-term care business; (2) Unum was experiencing less favorable policy terminations in connection with its long-term care business; (3) Unum’s long-term care business loss ratio would reach the upper 90% range; and (4) as a result of the foregoing, defendants’ statements about Unum’s business, operations, and prospects, including statements related to Unum’s long-term care reserves and capital management plans, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 13, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/unum-group/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 507418

ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Sibanye Gold Limited – SBGL

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Sibanye Gold Limited (NYSE: SBGL) from April 7, 2017 through June 26, 2018 (the “Class Period”). The lawsuit seeks to recover damages for Sibanye investors under the federal securities laws.

To join the Sibanye class action, go to http://pawarlawgroup.com/cases/sibanye-gold-limited/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Sibanye’s culture places short-term profits over safety; (2) consequently, almost half of South Africa’s 2018 mining fatalities occurred in Sibanye mines; and (3) as a result, defendants’ statements about Sibanye’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 27, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/sibanye-gold-limited/ or to discuss your rights or interests regarding this class action, please contact Vik Pawar of Pawar Law Group toll free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

CONTACT:

Vik Pawar, Esq.

Pawar Law Group P.C

20 Vesey Street Suite 1210

New York, NY 10007

Tel: (917) 261-2277

Toll Free: 888-589-9804

Fax: (212) -571-0938

vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 507424

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Vuzix Corporation – VUZI

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Vuzix Corporation (NASDAQ: VUZI): (i) pursuant and/or traceable to Vuzix’s registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Vuzix’s January 2018 secondary public offering; and/or (ii) between November 9, 2017 and March 20, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Vuzix investors under the federal securities laws.

To join the Vuzix class action, go to http://pawarlawgroup.com/cases/vuzix-corporation/ or call Vik Pawar, Esq. toll-free at 888-589-9804 or email vik@pawarlawgroup.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Vuzix used unlawful stock promotion tactics to boost its stock price; (2) Vuzix used misleading stock promotion tactics to raise nearly $30 million at an all-time high share price; and (3) as a result of the foregoing, defendants’ statements in the Registration Statement regarding Vuzix’s business, operations, and prospects, were materially false and/or misleading. When the true details entered the market, the lawsuit claims that investors suffered damages

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://pawarlawgroup.com/cases/vuzix-corporation/ to join the class action. You may also contact Vik Pawar of Pawar Law Group toll-free at 888-589-9804 or via email at vik@pawarlawgroup.com.

Pawar Law Group represents investors from around the world.

Vik Pawar, Esq.
Pawar Law Group P.C
20 Vesey Street Suite 1210
New York, NY 10007
Tel: (917) 261-2277
Toll-Free: 888-589-9804
Fax: (212) -571-0938
vik@pawarlawgroup.com
www.pawarlawgroup.com

SOURCE: Pawar Law Group

ReleaseID: 507412

The Joint Corp. Discusses Q1 2018 Performance and Growth Drivers in New SNNLive Video Interview with StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / July 30, 2018 / StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Peter Holt, President and CEO of The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, according to the company’s website (see here: www.thejoint.com). The video interview was recorded on Tuesday, June 5, 2018 at the LD Micro Invitational 2018 in Bel Air, CA.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Update with The Joint Corp. –
Chiropractic Care Provider Discusses Q1 2018 Performance and Growth Drivers

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About The Joint Corp.

Based in Scottsdale, Arizona, The Joint is an emerging growth company that is reinventing chiropractic by making quality care convenient and affordable for patients seeking pain relief and ongoing wellness. Its no-appointment policy and convenient hours and locations make care more accessible, and affordable membership plans and packages eliminate the need for insurance. With over 400 clinics nationwide and nearly 5 million patient visits annually, The Joint is a key leader in the chiropractic profession. For more information, visit www.thejoint.com or follow the brand on Twitter, Facebook, YouTube and LinkedIn.

For more information about The Joint Corp., please visit: www.thejoint.com

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for – all here on StockNewsNow.com.

StockNewsNow.com
info@stocknewsnow.com

SOURCE: StockNewsNow.com

ReleaseID: 507409

ORIX Corporation Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / ORIX Corporation Sponsored ADR (NYSE: IX) will be discussing their earnings results in their Q1 Earnings Call to be held on July 30, 2018 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-145DACE0572EA.

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 507056

CORRECTION: During the Week of July 16, Drone USA was Awarded 146 Contracts from the Army, Navy and Defense Logistics Agency (DLA) Totaling $1,016,377

WEST HAVEN, CT / ACCESSWIRE / July 30, 2018 / Drone USA, Inc. (OTCQB: DRUS) (”Drone USA” or the ”Company”), a service provider and reseller of drones and distributor of products to the U.S. Government, today announced that its subsidiary, Howco Distributing CT (”Howco”), two weeks ago received 146 contracts totaling $1,016,377 from the Army, Navy and the contract Defense Logistics Agency. It is important to note that it includes the $659,000 contract we announced last week.

Michael Bannon, Drone USA’s Chief Executive Officer, commented, ”This was a record week for us. For the first time our weekly contract award amount exceeded one million dollars.”

Matt Wiles, Howco’s VP of Business Operations, stated, ”Managing the high volume of government contracts like we do takes a dedicated team and robust processes. As we partner with more suppliers, I expect to see more weeks like this one in the future.”

About Howco Distributing Co.

Howco Distributing, a subsidiary of Drone USA, Inc., is a premier supplier of spare and replacement parts to a wide variety of Federal Government agencies, U.S. military prime contractors and commercial customers worldwide. Founded in 1990 and located in Vancouver, Washington, Howco’s services encompass bid solicitation, contract management, packaging and logistics for construction, transportation, mining and heavy equipment spare and replacement parts to customers worldwide utilizing a wide variety of supply chain solutions. Howco was the winner of 2017 United States Department of Defense Logistics Agency’s Commander’s Choice Supplier Award and the 2012 United States Department of Defense Logistics Agency’s Bronze Supplier Award.

About Drone USA, Inc.

Drone USA, Inc. (OTCQB: DRUS), headquartered in West Have, CT., is a service provider, manufacturer and reseller of drones and distributor of products to the U.S. Government. Our competitive advantage stems from offering superior service, high quality products and establishing and maintaining life-long customer friendships. Our primary markets are U.S. police, firemen, U.S. industry and the U.S. Government.

Forward-Looking Statements

Certain statements in this press release may be considered ”forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, operating expenses or net earnings; projections of growth; and assumptions relating to the foregoing. Such forward-looking statements are generally qualified by terms such as: ”plans, ”anticipates,” ”expects,” ”believes” or similar words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qualified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. These factors are discussed in greater detail in our Form 10 filed with the U.S. Securities and Exchange Commission.

Contacts:

Michael Bannon
Chief Executive Officer
mike@droneusainc.com

Hayden IR
Investor Relations
(917) 658-7878
hart@haydenir.com

SOURCE: Drone USA, Inc.

ReleaseID: 507406